This systematic review suggested a relationship between the levels of CSF biomarkers and the distribution of some clinical parameters (age at the onset of symptoms, seizure and movement disorder types, cognitive profiles, and efficacy of available treatments) in patients with GLUT1 deficiency syndrome (Table 1). This evidence concerns the gene SLC2A1 and movement disorder.